SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- A new partnership between Telesis Bio and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, will create efficient and scalable biofoundries, delivering solutions for sustainable and rapid on-premise synthesis of DNA. This innovative approach enabled by Telesis Bio's Gibson SOLA enzymatic reagent platform running on Beckman Coulter Life Sciences automation to ensures rapid, reliable, and highly scalable production of extremel ...

BOSTON and CHESTERFIELD, Mo., Sept. 24, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced its new partnership with NOVUS International, an innovator and leader in intelligent nutrition, to develop advanced feed additives designed to meet the evolving needs of the animal agriculture industry. By utilizing Ginkgo Enzyme Services, NOVUS will work with Ginkgo to build more efficient enzymes that can be produced costeff ...

OAKLAND, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Northern District of California Oakland Division has approved the following announcement of a proposed class action settlement that would benefit purchasers of Ginkgo Bioworks Holdings, Inc. common stock (NYSE: DNA): NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION TO: ALL PERSONS WHO (1) purchased or otherwise acquired shares in Ginkgo Bioworks Holdings, Inc. ("Ginkgo," includ ...

BOSTON, Sept. 18, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, proudly announces the launch of Ginkgo Datapoints to usher in the next era of biotechnology by making the training of AI models easier and more efficient. Ginkgo Datapoints is specialized in generating large, high-quality biological datasets with a fast turnaround time and at a competitive price per datapoint with a streamlined deal structure. Ginkgo Datapoi ...

The company is forging ahead with next-generation drug development solutions. Bioengineering specialist Ginkgo Bioworks Holdings (DNA 9.31%) delivered some badly needed good news for investors on Tuesday. Those folks commensurately rewarded the company by trading up its stock during that day's session, and it closed more than 9% higher in price. That was more than enough to crush the broader market that day, at least in respect to the stagnating S&P 500 index. Two new products introduced Ginkgo's news was c ...

Protein large language model (LLM) designed to help enterprises accelerate drug development coming to Google Cloud's Vertex AI Model Garden soon; one of the first-of-its-kind in the industry Model API programmable interface now available for individual scientists and researchers to quickly test and advance work BOSTON, Sept. 17, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced two new offerings that ...

VANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies and Variational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, announced today a research collaboration aimed at leveraging each company's expertise to identify and develop novel small-molecule therapies against DNA-damage response (DDR) t ...

Could this beaten-down stock turn things around in the near future? If a stock is down more than 90% during the past year, you know there's something seriously wrong with the underlying business. Things have gotten so bad for biotech company Ginkgo Bioworks Holdings (DNA 2.29%) that it recently had to do a 1-for-40 reverse stock split to keep its share price up and stay listed on the New York Stock Exchange. It has been in the midst of a stunning free fall as investors appear to have lost patience with the ...

OAKLAND, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Northern District of California Oakland Division has approved the following announcement of a proposed class action settlement that would benefit purchasers of Ginkgo Bioworks Holdings, Inc. common stock (NYSE: DNA): NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION TO: ALL PERSONS WHO (1) purchased or otherwise acquired shares in Ginkgo Bioworks Holdings, Inc. ("Ginkgo," includ ...

The risks may resolve in a year or so but seizing the opportunities will take longer. When a stock you own is struggling to retain value, it pays to know what new problems might lie awaiting in its future. To have the conviction to retain your shares through a dip, you'll also need to appreciate the upcoming opportunities that might make your patience worth the while. Ginkgo Bioworks (DNA -5.64%) is facing a pair of big risks right now, but it also has a pair of big opportunities that could be enough to tur ...